Cathepsin G Antibody - #AF5167

(1)   (7)  
Product: Cathepsin G Antibody
Catalog: AF5167
Description: Rabbit polyclonal antibody to Cathepsin G
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 28 kDa; 29kD(Calculated).
Uniprot: P08311
RRID: AB_2837653

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
Cathepsin G Antibody detects endogenous levels of total Cathepsin G.
RRID:
AB_2837653
Cite Format: Affinity Biosciences Cat# AF5167, RRID:AB_2837653.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CATG; CATG_HUMAN; Cathepsin G; Cathepsin G precursor; CathepsinG; CG; Ctsg; CTSG protein; MGC23078;

Immunogens

Immunogen:
Uniprot:

P08311(CATG_HUMAN) >>Visit HPA database.

Gene(ID):
CTSG(1511)
Description:
Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride.
Sequence:
MQPLLLLLAFLLPTGAEAGEIIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVLTAAHCWGSNINVTLGAHNIQRRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRRNRNVNPVALPRAQEGLRPGTLCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYDPRRQICVGDRRERKAAFKGDSGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRTTMRSFKLLDQMETPL

PTMs - P08311 As Substrate

Site PTM Type Enzyme
S233 Phosphorylation

Research Backgrounds

Function:

Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride.

Subcellular Location:

Cell surface.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

(Microbial infection) Interacts with M.tuberculosis protein Rv3364c.

Family&Domains:

Belongs to the peptidase S1 family.

Research Fields

· Cellular Processes > Transport and catabolism > Lysosome.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Neuroactive ligand-receptor interaction.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Immune diseases > Systemic lupus erythematosus.

· Organismal Systems > Endocrine system > Renin-angiotensin system.   (View pathway)

References

1). Identification of a novel immune gene panel in tongue squamous cell carcinoma. American Journal of Translational Research, 2022 (PubMed: 35702068) [IF=2.2]

Application: IHC    Species: Human    Sample: tumor

Figure 11 Clinical validation for the predicting efficiency of immune-gene panel. A. Relative expression levels of CTSG, CXCL13 and VEGFA in tongue squamous cell carcinoma samples among different T stages in TCGA dataset. B. Relative expression levels of CTSG, CXCL13 and VEGFA in tongue squamous cell carcinoma samples among different N stages in TCGA dataset. C. Clinical validation of VEGFA, CXCL13 and CTSG expression levels in tumor samples at pathologic T1, T3 and T4 stage with the help of IHC staining images. D. Clinical validation of VEGFA, CXCL13, and CTSG expression levels in tumor samples at pathological N0 and N2 stages with the help of IHC staining images. E-G. Clinical validation for accumulation of Th17 cells, CD4+ T cells and CD8+ T cells in TSCC by immunofluorescent staining.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.